LYMPHOMA CONNECT has summarised the highlights from ASH 2019 for you. Highlights on Chronic Lymphocytic Leukaemia by Dr. Alexey Danilov, OHSU, Knight Cancer Institute, Portland, USA.
Watch the video and download the slides
LYMPHOMA CONNECT has summarised the highlights from ASH 2019 for you. Highlights on Chronic Lymphocytic Leukaemia by Dr. Alexey Danilov, OHSU, Knight Cancer Institute, Portland, USA.
Watch the video and download the slides
Dr Jessica Okosun is a Cancer Research UK Clinician Scientist at the Barts Cancer Institute and an Honorary Consultant Haematologist at St Bartholomew’s Hospital, London UK, specialising in lymphomas. She received her BA in Natural Sciences (Pathology) and qualified in medicine from the University of Cambridge in 2004. She was a recipient of the Kay Kendall Leukaemia Fund’s Junior Research Fellowship, completing her PhD in 2015 from Queen Mary, University of London. Her research interests are focussed on understanding the origin, heterogeneity and evolution of lymphomas, particularly follicular lymphomas, in a bid to define novel biomarkers and therapeutic strategies. Her research has led to several awards including the EHA/ASH Translational Research Training in Haematology award and the UK’s Royal College of Pathologist Specialty Research Medal in Haematology. She is an active member of the UK’s National Cancer Research Institute (NCRI) High Grade Lymphoma Subgroup, Hodgkin lymphoma subgroup and the Primary CNS Lymphoma (PCNSL) Working Party. She chairs the Barts Cancer Centre’s Patient and Public Research Advisory Group.
BeiGene and Gilead Sciences.
A 3-part video series on managing early RRMM from leading medical experts
Medical experts discuss the latest learnings from clinical practice
Episode 6: Lymphoma Update: SWOG S1826 trial
Highlights from the ASH Annual Meeting
Dr Hans Lee summarises the highlights from the phase 3 DETERMINATION trial: Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM)
Episode 3: Choosing the Best Treatment Regimen in Patients with High-Risk Cytogenetics